High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease
- PMID: 20354791
- PMCID: PMC3008397
- DOI: 10.1007/s10545-010-9070-1
High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease
Abstract
Background: In Gaucher disease (GD), lysosomal glucocerebrosidase deficiency results in glucosylceramide accumulation in macrophage lysosomes. Hepatocytes do not accumulate glucosylceramide due in part to biliary secretion. Although gallstones (GS) occur in type 1 Gaucher disease (GD1), the chemical nature of stones, their association with metabolic parameters, and whether bile composition is altered are not understood. We assessed the prevalence of GS, their chemical composition, biliary lipids, and associated metabolic factors.
Methods: The study cohort comprised 417 patients comprehensively evaluated for GD1 severity. Ascertainment of GS, fasting lipoprotein profile, and bile lipid analyses were performed.
Results: The prevalence of GS in GD1 was 32%. Compared with men, the prevalence of GS was higher in women, increasing from 4.2% and 11.8% at age 20-29 years to 71% and 60% at age >70 years, respectively. Patients with GS were more likely to be asplenic (p < 0.0001), older (p < 0.0001), have higher low-density lipoprotein (LDL) cholesterol (p = 0.002), and more severe GD1 disease compared with those without GS. On multiple logistic regression analysis, factors associated with GS were age (p < 0.001), female sex (p = 0.03), and splenectomy (p = 0.005). Compared with the general population, prevalence of GS was approximately 5-fold higher. Bile lipid analyses revealed cholesterol stones in five patients and pigment stones in one. Bile lipid composition was abnormal and contained glucosylceramide.
Conclusions: Our results point to a metabolic syndrome in GD1 consisting of a propensity to cholesterol GS, low high-density lipoprotein (HDL) cholesterol, LDL cholesterol, and body mass index (BMI) associated with abnormal biliary lipid secretion.
Conflict of interest statement
Competing interest: None declared.
Figures
Similar articles
-
Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants.J Gastrointestin Liver Dis. 2016 Dec;25(4):447-455. doi: 10.15403/jgld.2014.1121.254.zim. J Gastrointestin Liver Dis. 2016. PMID: 27981300
-
Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.Am J Hematol. 2010 May;85(5):340-5. doi: 10.1002/ajh.21684. Am J Hematol. 2010. PMID: 20425796 Free PMC article.
-
Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals.Hepatol Commun. 2025 Jan 7;9(1):e0621. doi: 10.1097/HC9.0000000000000621. eCollection 2025 Jan 1. Hepatol Commun. 2025. PMID: 39774103 Free PMC article.
-
Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism.Crit Rev Oncog. 2013;18(3):235-46. doi: 10.1615/critrevoncog.2013006145. Crit Rev Oncog. 2013. PMID: 23510066 Free PMC article. Review.
-
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease.Blood Cells Mol Dis. 2018 Feb;68:74-80. doi: 10.1016/j.bcmd.2016.10.012. Epub 2016 Oct 20. Blood Cells Mol Dis. 2018. PMID: 27839982 Review.
Cited by
-
Liver involvement in patients with Gaucher disease types I and III.Mol Genet Metab Rep. 2020 Jan 7;22:100564. doi: 10.1016/j.ymgmr.2019.100564. eCollection 2020 Mar. Mol Genet Metab Rep. 2020. PMID: 32099816 Free PMC article.
-
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.Int J Mol Sci. 2017 Feb 17;18(2):441. doi: 10.3390/ijms18020441. Int J Mol Sci. 2017. PMID: 28218669 Free PMC article. Review.
-
Insight into the mechanism of gallstone disease by proteomic and metaproteomic characterization of human bile.Front Microbiol. 2023 Dec 4;14:1276951. doi: 10.3389/fmicb.2023.1276951. eCollection 2023. Front Microbiol. 2023. PMID: 38111640 Free PMC article.
-
Natural history and management of liver dysfunction in lysosomal storage disorders.World J Hepatol. 2022 Oct 27;14(10):1844-1861. doi: 10.4254/wjh.v14.i10.1844. World J Hepatol. 2022. PMID: 36340750 Free PMC article. Review.
-
Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.J Inherit Metab Dis. 2013 May;36(3):555-63. doi: 10.1007/s10545-012-9529-3. Epub 2012 Sep 14. J Inherit Metab Dis. 2013. PMID: 22976766 Clinical Trial.
References
-
- Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20:981–996. - PubMed
-
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428. - PubMed
-
- Hoblinger A, Lammert F. Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers. Curr Opin Gastroenterol. 2008;24:363–371. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K24DK066306/DK/NIDDK NIH HHS/United States
- T32 DK007356/DK/NIDDK NIH HHS/United States
- R01 DK056626/DK/NIDDK NIH HHS/United States
- K24 DK066306/DK/NIDDK NIH HHS/United States
- R29 DK048873/DK/NIDDK NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- T32DK007356/DK/NIDDK NIH HHS/United States
- R01 DK048873/DK/NIDDK NIH HHS/United States
- P30DK34989/DK/NIDDK NIH HHS/United States
- P30 DK034989/DK/NIDDK NIH HHS/United States
- DK56626/DK/NIDDK NIH HHS/United States
- DK48873/DK/NIDDK NIH HHS/United States
- R37 DK048873/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical